AI Summary & Key Takeaways
AI InsightThe median progression-free survival (PFS) after treatment with aflibercept was 5.13 months, while the median overall survival (OS) was 11.9 months.
📌 3 Key Takeaways
Abstract
Colorectal cancer is one of the most common malignancies worldwide, and new treatment options are continually emerging. This study aimed to assess the effects and side effects of aflibercept, one of the current treatment options for the condition. We included fifty-two patients diagnosed with colorectal cancer at the Bursa Uludağ University Medical Oncology Department between January 2014 and December 2020. These patients either presented with metastasis at the time of diagnosis or developed it during follow-up and were subsequently treated with aflibercept. Two patients were excluded from the study due to irregular follow-up. Among the patients included, 74% had metastatic disease at diagnosis, and 70% had tumors located in the left colon. KRAS mutations were identified in 56% of the patients. Aflibercept was the most commonly preferred second-line treatment. The median progression-free survival (PFS) after treatment with aflibercept was 5.13 months, while the median overall survival (OS) was 11.9 months. No significant difference was observed in overall survival between patients receiving aflibercept as second-line treatment and those receiving it as later lines. The frequency of side effects was consistent with existing literature; notably, significant proteinuria was observed during treatment.
Özet
Kolorektal kanser, dünya çapında en sık görülen malignitelerden birisidir ve sürekli olarak yeni tedavi seçenekleri ortaya sunulmaktadır. Bu çalışma, mevcut tedavi seçeneklerinden birisi olan aflibercept tedavisinin etki ve yan etkilerini göstermeyi amaçlamaktadır. Çalışmamıza Ocak 2014 ve Aralık 2020 tarihleri arasında Bursa Uludağ Üniversitesi Tıbbi Onkoloji Anabilim Dalı’nda kolorektal kanser tanısı almış 52 hasta dahil edildi. Bu hastaların tamamında tanı anında veya takiplerde gelişen metastaz mevcuttu. 2 hasta takip aralıklarının düzensiz olması nedeni ile çalışmadan çıkartıldı. Dahil edilen hastaların %74’ünde tanı anında metastaz mevcuttu ve %70’inde tümör sol kolon yerleşimliydi. Çalışma grubunun %56’sında KRAS mutasyonu saptandı. İkinci basamak tedavide en sık tercih edilen tedavi ajanı aflibercept olarak bulundu. İkinci ve sonraki basamaklarda aflibercept tedavisi almak arasında genel sağkalımda anlamlı fark izlenmedi. Yan etki profili ve sıklığı literatür ile uyumluydu, özellikle proteinüri açısından anlamlı fark saptandı.